

09-18-02

CASE OP/4-31881A

1646
#8
DMT
10-2502



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EZ 820027976 US</u> Express Mail Label Number	<u>September 17, 2002</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1646

BRAZZELL ET AL.

APPLICATION NO: 10/080,797

FILED: FEBRUARY 21, 2002

FOR: METHOD OF TREATING OCULAR NEOVASCULARIZATION

RECEIVED

SEP 19 2002

CH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



David E. Wildman
Attorney for Applicants
Reg. No. 40,226

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6946

Date: 9/17/02